(246 days)
Yes
The device description explicitly states that the AliveCor QT Service "utilizes various internal algorithms including deep neural networks (DNN) to analyze an ECG to compute the QT interval." DNNs are a type of artificial neural network, which falls under the umbrella of AI and ML.
No.
The device measures QT and QTc intervals from ECGs; it does not provide any therapy or treatment.
Yes
The device analyzes previously acquired ECGs to measure QT and QTc intervals, which are used to aid in a diagnosis of certain cardiac conditions.
Yes
The device is explicitly described as a "cloud-based Software as a Medical Device (SaMD)" and its function is to analyze previously acquired ECG data. It does not include or require any specific hardware component for its operation beyond the input data itself.
Based on the provided information, the AliveCor QT Service is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for the diagnosis, treatment, or prevention of disease.
- AliveCor QT Service Function: The AliveCor QT Service analyzes previously acquired electrocardiograms (ECGs). ECGs are recordings of the electrical activity of the heart, obtained externally from the body. They are not specimens taken from the body for examination in a laboratory setting.
- Intended Use: The intended use is to measure QT and QTc intervals from ECGs, which is a form of physiological measurement, not the analysis of biological specimens.
Therefore, while it is a medical device and a Software as a Medical Device (SaMD), it falls under a different regulatory category than In Vitro Diagnostics.
No
The letter does not explicitly state that the FDA has reviewed, approved, or cleared a PCCP for this specific device. The provided text for "Control Plan Authorized (PCCP) and relevant text" indicates "Not Found".
Intended Use / Indications for Use
AliveCor QT Service analyses 30 seconds of a previously acquired electrocardiogram (ECG) from AliveCor designed 6-Lead ambulatory ECG devices analyzed as normal sinus rhythm for QT interval measurements.
AliveCor QT Service is intended for use in a professional medical facility, such as a hospital, clinic, or doctor's office by a qualified health care professional, including trained ECG technician.
AliveCor QT Service is indicated for use on adult patients (older than 18 years). The device has not been tested for and is not intended for pediatric use. The service is not intended for use in life supporting, or sustaining systems, or continuous ECG monitors, or cardiac alarm devices, or OTC use only devices.
Product codes
DQK, DPS
Device Description
AliveCor QT Service is a cloud-based Software as a Medical Device (SaMD) that is used to measure the QT and heart-rate corrected QT ("QTc") interval measurements from electrocardiograms (ECG) recorded from adult patients (older than 18 years) using AliveCor designed 6-Lead ambulatory ECG devices. AliveCor QT Service provides QT and QTc interval measurements only on ECGs analyzed as Normal Sinus Rhythm by KardiaAI (K201985).
AliveCor QT Service is a prescription (Rx) use only device intended for use by qualified healthcare professionals, including trained ECG technicians. Healthcare professionals can access AliveCor QT Service over the internet from patient management and ECG storage Medical Device Data Systems (MDDS), or from other prescription-use only medical data software devices. These devices provide a previously recorded ECG from an AliveCor-designed 6-Lead ambulatory ECG device, such as the KardiaMobile 6L (K210753), in a compatible format using the AliveCor QT Service's REST-based application program interface (API). REST or REpresentational State Transfer is a software methodology that defines rules for creating web services to access resources over Hypertext Transfer Protocol (HTTP). AliveCor QT Service responds to the analysis request with the following measurements:
- QT interval, measured from the first 30 seconds of the ECG
- Heart-rate corrected QT (QTc) interval based on the Bazett's formula and the Fridericia's formula
AliveCor QT Service utilizes various internal algorithms including deep neural networks (DNN) to analyze an ECG to compute the QT interval. AliveCor QT Service also includes algorithms to compute the RR-interval, which is used to provide both the Bazett's and Fridericia corrected QTc intervals. These algorithms were trained and validated on datasets with ECGs from patients representative of the device's intended use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
AliveCor QT Service utilizes various internal algorithms including deep neural networks (DNN) to analyze an ECG to compute the QT interval.
Input Imaging Modality
electrocardiogram (ECG)
Anatomical Site
Not Found
Indicated Patient Age Range
adult patients (older than 18 years)
Intended User / Care Setting
professional medical facility, such as a hospital, clinic, or doctor's office by a qualified health care professional, including trained ECG technician.
Description of the training set, sample size, data source, and annotation protocol
The training included more than 750K ECGs from over 250K patients. The training dataset included more than 200K ECGs with approximately 49% data from females, approximately 70% from subjects who were reported as whites, 3% non-whites, and 27% from those who did not report their race.
Description of the test set, sample size, data source, and annotation protocol
The validation was conducted on two datasets. The first dataset included more than 34K ECGs with approximately 51% data from females, approximately 80% from subjects who were reported as whites, 3.6% non-whites, and 17% from those who did not report their race. The second dataset included 226 ECGs with approximately 60% data from females, approximately 87% from subjects who were reported as whites, 3.2% non-whites, and 10% from those who did not report their race.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical testing was conducted to assess algorithm performance and to verify that the AliveCor QT Service estimated QT and heart-rate corrected QT intervals have a mean interval difference
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 11, 2022
AliveCor, INC. % Prabhu Raghavan Principal Consultant MDQR, LLC 189 N. Bernardo Ave. Suite 100 Mountain View, California 94043
Re: K212662
Trade/Device Name: AliveCor QT Service Regulation Number: 21 CFR 870.1425 Regulation Name: Programmable diagnostic computer Regulatory Class: Class II Product Code: DQK, DPS
Dear Prabhu Raghavan:
The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated April 26, 2022. Specifically, FDA is updating this SE Letter (e.g., typo in correspondent address) as an administrative correction.
Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Jennifer Shih Kozen, OHT2: Office of Cardiovascular Devices, 301-796-5813, Jennifer.Shih(@fda.hhs.gov.
Sincerely,
Jennifer W. Shih -S
Jennifer Shih Kozen Assistant Director Division of Cardiac Electrophysiology, Diagnostics and Monitoring Devices Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
1
Image /page/1/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
April 26, 2022
AliveCor, Inc. % Prabhu Raghavan Principal Consultant MDQR, LLC 444 Castro Street, Suite 600 Mountain View, California 94041
Re: K212662
Trade/Device Name: AliveCor QT Service Regulation Number: 21 CFR 870.1425 Regulation Name: Programmable Diagnostic Computer Regulatory Class: Class II Product Code: DQK, DPS Dated: March 25, 2022 Received: March 28, 2022
Dear Prabhu Raghavan:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
2
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE(@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Jennifer W. Shih -S
Jennifer Shih Kozen Assistant Director Division of Cardiac Electrophysiology, Diagnostics and Monitoring Devices Office of Cardiovascular Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K212662
Device Name AliveCor QT Service
Indications for Use (Describe)
AliveCor QT Service analyses 30 seconds of a previously acquired electrocardiogram (ECG) from AliveCor designed 6-Lead ambulatory ECG devices analyzed as normal sinus rhythm for QT interval measurements.
Alive or OT Service is intended for use in a professional medical facility, such as a hospital, clinic, or doctor's office by a qualified health care professional, including trained ECG technician.
Alive Or OT Service is indicated for use on adult patients (older than 18 years). The device has not been tested for and is not intended for pediatric use. The service is not in life supporting, or sustaining systems, or continuous ECG monitors, or cardiac alarm devices, or OTC use only devices.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Image /page/4/Picture/0 description: The image shows the word "AliveCor" in a teal color. The font is sans-serif and the letters are evenly spaced. There is a registered trademark symbol to the right of the word.
510(k) Summary for K212662
Prepared in accordance with the requirements of 21 CFR 807.92
Submitter Information [807.92(a)(1)]
| Submitter/Applicant | AliveCor, Inc.
189 N. Bernardo Ave.
Mountain View, CA 94043
Phone: 650-396-8553
Fax: 650-282-7932 |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary Contact Person | Prabhu Raghavan
Regulatory Consultant for AliveCor
MDQR, LLC
189 N. Bernardo Ave.
Mountain View, CA 94043
Phone: 408-316-5707
Fax: 650-282-7932
Email: prabhu@mdqr.solutions |
| Submitter and
Secondary Contact Person | Susan Noriega
VP of Regulatory Affairs, Clinical Affairs and Quality
189 N. Bernardo Ave. Suite 100
Mountain View, CA 94043
Phone: 650-793-1966
Fax: 650-282-7932
Email: snoriega630@alivecor.com |
| Date Prepared | April 25, 2022 |
| Device Information [807.92(a)(2)] | |
| Trade Name
Common Name
Classification
Device Class
Product Code
Subsequent Product Code | AliveCor QT Service
Programmable diagnostic computer
21 CFR§870.1425
II
DQK, Computer, Diagnostic, Programmable
DPS, Electrocardiograph |
Predicate Information [807.92(a)(3)]
| Predicate | K170155, GE EK12 Algorithm |
|---|---|
| Reference Device | K201985, AliveCor KardiaAI |
Device Description [807.92(a)(4)]
AliveCor QT Service is a cloud-based Software as a Medical Device (SaMD) that is used to measure the QT and heart-rate corrected QT ("QTc") interval measurements from
5
electrocardiograms (ECG) recorded from adult patients (older than 18 years) using AliveCordesigned 6-Lead ambulatory ECG devices. AliveCor QT Service provides QT and QTc interval measurements only on ECGs analyzed as Normal Sinus Rhythm by KardiaAI (K201985).
AliveCor QT Service is a prescription (Rx) use only device intended for use by qualified healthcare professionals, including trained ECG technicians. Healthcare professionals can access AliveCor OT Service over the internet from patient management and ECG storage Medical Device Data Systems (MDDS), or from other prescription-use only medical data software devices. These devices provide a previously recorded ECG from an AliveCor-designed 6-Lead ambulatory ECG device, such as the KardiaMobile 6L (K210753), in a compatible format using the AliveCor QT Service's REST-based application program interface (API). REST or REpresentational State Transfer is a software methodology that defines rules for creating web services to access resources over Hypertext Transfer Protocol (HTTP). AliveCor QT Service responds to the analysis request with the following measurements:
- QT interval, measured from the first 30 seconds of the ECG
- Heart-rate corrected QT (QTc) interval based on the Bazett's formula and the Fridericia's ● formula
AliveCor QT Service utilizes various internal algorithms including deep neural networks (DNN) to analyze an ECG to compute the QT interval. AliveCor QT Service also includes algorithms to compute the RR-interval, which is used to provide both the Bazett's and Fridericia corrected OTc intervals. These algorithms were trained and validated on datasets with ECGs from patients representative of the device's intended use. The training included more than 750K ECGs from over 250K patients. The training dataset included more than 200K ECGs with approximately 49% data from females, approximately 70% from subjects who were reported as whites, 3% nonwhites, and 27% from those who did not report their race The validation was conducted on two datasets. The first dataset included more than 34K ECGs with approximately 51% data from females, approximately 80% from subjects who were reported as whites, 3.6% non-whites, and 1 7% from those who did not report their race. The second dataset included 226 ECGs with approximately 60% data from females, approximately 87% from subjects who were reported as whites, 3.2% non-whites, and 10% from those who did not report their race.
Indications for use [807.92(a)(5)]
AliveCor QT Service analyses 30 seconds of a previously acquired electrocardiogram (ECG) from AliveCor designed 6-Lead ambulatory ECG devices analyzed as normal sinus rhythm for QT interval measurements.
AliveCor OT Service is intended for use in a professional medical facility, such as a hospital, clinic, or doctor's office by a qualified health care professional, including trained ECG technician.
AliveCor QT Service is indicated for use on adult patients (older than 18 years). The device has not been tested for and is not intended for pediatric use. The service is not intended for use in life supporting, or sustaining systems, or continuous ECG monitors, or cardiac alarm devices, or OTC use only devices.
6
510(k) Summary for K212662, AliveCor QT Service AliveCor, Inc.
Substantial Equivalence
The Substantial Equivalence utilizes one predicate device and one reference device, namely:
-
- Predicate: K170155, EK12 Algorithm, that analyzes ECGs to provide rhythm and measurements including QT interval measurements.
-
- Reference Device: K201985, KardiaAI, which is an API library that analyzes ECGs from AliveCor-designed ECG devices and provides rhythm analysis. The reference device, like the subject device is used to analyze ECGs recorded from AliveCordesigned ambulatory ECGs including the K210753, KardiaMobile 6L, an AliveCordesigned 6-Lead ambulatory ECG device that the subject device is compatible with. The subject device also incorporates this reference device internally to perform rhythm analysis to determine if the provided ECG is Normal Sinus Rhythm.
AliveCor QT Service has the same intended use as the predicate device, K170155, GE EK12 Algorithm. Both devices analyze prerecorded multi-lead ECG signals and measure the QT and heart-rate corrected OT intervals. Both devices are intended to be used by qualified health care professional, including trained ECG technicians. The subject device additionally shares key safety and technological characteristics with the predicate device: both devices are SaMDs that may not be used for active patient monitoring and do not provide any time sensitive information, continuous display of information, alarms, or alerts intended to alert a caregiver to take an immediate clinical action. Both devices do not directly interface with the patient, and both are provided digital ECG samples and output digital information containing the requested analysis. Both devices are provided in the form of a service. The predicate is additionally provided as a compiler linked library and as a command-line interface application.
The subject device utilizes a mix of algorithms that utilize adaptive filters, and features extracted using signal processing to compute a representative ECG beat, which is then used by a deep neural network to compute the QT interval measurement1. The predicate computes a representative beat and uses ECG signal processing, pattern recognition, regression methods, as well as modeling of cardiac action potentials to establish the key time points in the overall ECG and thus compute the QT interval2. Both devices account for poor T-waves in the ECG. Any differences between the technological characteristics of the interval measurement algorithms have been evaluated through performance testing and do not raise different questions of safety or effectiveness. Differences between the subject device and the predicate have been tested to ensure that the device meets its intended use. Therefore, AliveCor QT Service is substantially equivalent to the predicate device.
1 Giudicessi, Schram, et al. Artificial Intelligence-Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device. Circulation. 2021 Mar 30;143(13):1274-1286. doi: 10.1161/CIRCULATIONAHA.120.050231. Epub 2021 Feb 1.
2 Xue J. Q. (2009). Robust QT interval estimation--from algorithm to validation. Annals of nominvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 14 Suppl 1(Suppl 1), S35-S41. https://doi.org/10.1111/j.1542-474X.2008.00264.x
7
| Feature | AliveCor QT Service
(Subject Device) | K170155 EK12
Algorithm
(Predicate Device) | K201985 KardiaAI
(Reference Device) |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Product Code | DQK, Computer,
Diagnostic, Programmable
DPS, Electrocardiograph | MHX, Monitor,
Physiological, Patient
(With Arrhythmia
Detection or
Alarms) | DQK, Computer,
Diagnostic, Programmable
DPS, Electrocardiograph |
| Regulation | 21 CFR§870.1425,
Programmable diagnostic
computer | 21 CFR 870.1025,
Arrhythmia detector and
alarm | 21 CFR§870.1425,
Programmable diagnostic
computer |
| Classifi-cation | II | II | II |
| Indications for
Use | AliveCor QT Service
analyses 30 seconds of a
previously acquired
electrocardiogram (ECG)
from AliveCor designed 6-
Lead ambulatory ECG
devices analyzed as normal
sinus rhythm for QT
interval measurements.
AliveCor QT Service is
intended for use in a
professional medical
facility, such as a hospital,
clinic, or doctor's office by
a qualified health care
professional, including
trained ECG technician.
AliveCor QT Service is
indicated for use on adult
patients (older than 18
years). The device has not
been tested for and is not
intended for pediatric use.
The service is not intended
for use in life supporting,
or sustaining systems, or | EK12 Algorithm analyzes
ten or more seconds of a
previously acquired
electrocardiogram (ECG)
from physiological ECG
signal recording devices
for rhythm and
measurements. EK12
Algorithm is used to create
reports intended for use by
a Qualified Medical
Professional, including a
trained ECG Technician
operating within
Independent Diagnostic
Testing Facility (IDTF)
requirements and
performance standards for
the review and assessment
of an ECG.
EK12 Algorithm is
indicated for use on adults
and pediatric patients older
than 2 years.
The device is intended for
use in an IDTF or a | KardiaAI is a software
analysis library intended to
assess ambulatory
electrocardiogram (ECG)
rhythms from adult
subjects (when prescribed
or used under the care of a
physician). The device
supports analyzing data
recorded in compatible
formats from any
ambulatory ECG devices
such as event recorders, or
other similar devices. The
library is intended to be
integrated into other device
software. The library is
not intended for use in life
supporting, or sustaining
systems, or ECG monitors,
or cardiac alarm devices,
or OTC use only devices.
The KardiaAI library
provides the following
capabilities:
●
Filtering ECG noise, |
| Feature | AliveCor QT Service
(Subject Device) | K170155 EK12
Algorithm
(Predicate Device) | K201985 KardiaAI
(Reference Device) |
| | continuous ECG monitors,
or cardiac alarm devices,
or OTC use only devices. | professional medical
facility, such as a hospital,
clinic, or doctor's office. | Reporting heart rate measurement from ECGs,Detecting noisy ECGs,Reporting ECG rhythm analysis for the presence of sinus rhythm, atrial fibrillation, bradycardia, and tachycardia; for ECGs detected as sinus rhythm, detecting normal sinus rhythm, sinus rhythm with wide QRS, sinus rhythm with premature ventricular contractions (PVC), and sinus rhythm with supraventricular ectopy,Detecting QRS complexes in an ECG,For ECGs detected as sinus rhythm, classifying individual beats as a PVC or non-PVC beat, andGenerating an average beat from an ECGThe device is not intended for use in patients who have pacemakers, ICDs, or other implanted electronic devices |
| Target
population | Adults (over 18) | Adults and pediatric
patients older than 2 years | Adults (over 18) |
| Feature | AliveCor QT Service
(Subject Device) | K170155 EK12
Algorithm
(Predicate Device) | K201985 KardiaAI
(Reference Device) |
| Indicated Use
Method | Prescription Use | Prescription Use | Prescription Use |
| Form Factor | Software only | Software only | Software only |
| Compatible
ECG Leads | Lead-I and Lead-II from
AliveCor-designed six-lead
ambulatory ECG | 12-lead or any subset of
12-leads | Lead-I from AliveCor-
designed ambulatory ECG |
| Technology | Software algorithm | Software algorithm | Software algorithm |
| ECG Analysis | QT and heart-rate
corrected QT intervals | Rhythm and measurement
analysis including QT and
heart-rate corrected QTc
intervals | Rhythm analysis |
| Technological
characteristics | Adaptive filtering, signal
processing, deep neural
networks | Adaptive filtering, signal
processing, regression
models | Adaptive filtering, signal
processing, deep neural
networks |
Comparison of Technological Characteristics with the Predicate Device [807.92(a)(6)]
8
Comparison of Technological Characteristics with the Predicate Device [807.92(a)(6)]
9
Comparison of Technological Characteristics with the Predicate Device [807.92(a)(6)]
Performance Data [807.92(b)]
All necessary testing was conducted on AliveCor QT Service to support a determination of substantial equivalence to the predicate device.
Nonclinical Testing Summary [807.92(b)(1)]
AliveCor conducted bench performance testing of the subject device to validate that the device meets its performance specifications and to demonstrate that, in light of the technological differences between AliveCor OT Service and its predicate, the subject device is at least as safe and as effective as the predicate device for the same intended use.
Nonclinical testing was conducted to assess algorithm performance and to verify that the AliveCor QT Service estimated QT and heart-rate corrected QT intervals have a mean interval difference ≤ ± 20ms and a standard deviation of interval difference ≤ 25ms when compared to an expert annotated reference interval from a supine. diagnostic bandwidth, 12-lead ECG. Algorithm performance was evaluated using standards-based and AliveCor proprietary ECG databases. The databases were selected or developed to demonstrate that the QT interval measurement is accurate and can be used to measure the interval on ECGs recorded from AliveCor designed six-lead ECG devices by adults. Additionally, the subject device and the predicate were comparatively evaluated against appropriate databases to demonstrate substantially equivalent performance.
10
510(k) Summary for K212662, AliveCor QT Service AliveCor, Inc.
In summary, the results of the nonclinical testing demonstrate that AliveCor QT Service performs to its specifications, meets its intended use with substantially equivalent performance to that of the predicate device and does not raise different questions of safety or effectiveness.
Clinical Testing Summary [807.92(b)(2)]
No clinical testing was required to establish substantial equivalence.
Conclusions [807.92(b)(3)]
AliveCor QT Service has the same intended use as the predicate device, and the labeling differences do not raise different questions of safety or effectiveness. Therefore, AliveCor QT Service is substantially equivalent to the predicate device.